Nicoline Hoogerbrugge full professorNicoline Hoogerbrugge is a medical specialist and full professor in hereditary cancer. She is chair of the multidisciplinary expert center in Hereditary Cancer of the Radboud University Medical Center. Research interests include the molecular basis of hereditary cancer and their implementations in understanding carcinogenesis. Current projects focus on hereditary colorectal cancer, polyposis and hereditary pediatric cancer.
- Chair of the European Reference Network Genetic Tumour Risk Syndromes (since 2017)
- Member of the European Board of coordinators of the European Reference Networks (since 2017)
- Chair of the annual ESHG Spring course in hereditary cancer (since 2016)
- Member of the board of InSIGHT (international society for hereditary Gastrointestinal Tumors) (since 2016)
- Chair of the Radboudumc committee for ethics (since 2015)
- Chair of the writing committee of the National Guidelines for hereditary colorectal cancer (since 2014)
- Chair of the Radboud Expert Center in Cancer Prevention (since 2013)
- Chair of the scientific advisory board colorectal cancer: Maag-Lever-Darm stichting (since 2012)
- Chair of the Radboud Expert Center in Hereditary Cancer (since 2001)
- Member of national and international scientific societies
Field of studyHuman Genetics
Research Cllinical Cancer GeneticsA known hereditary origin of cancer may enable early disease detection, targeted surveillance, and result in effective prevention strategies. Remarkable advances have been made in understanding the human genome’s contribution to cancer. Our aim is to identify new cancer related genes and genetic mechanisms and to apply new developments into the practice of oncology and preventive medicine.
The genetic origin of hereditary cancerWithin this subtheme we aim to identify novel cancer predisposing genes and genetic mechanisms in families with a high, but unexplained, risk of gastric and colorectal cancer and in patients with malformation syndromes and cancer.
In addition, we aim at resolving the biological and clinical significance of these genes, including the role of recently identified EPCAM deletions in the epigenetic silencing of the MSH2 gene in Lynch syndrome.